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Abstract
Traditionally, ventilator-associated pneumonia (VAP) has been
treated either with double drug therapy or with monotherapy.
Double drug therapy has been used to increase spectrum, for
possible synergy, and to decrease the emergence of resistance.
VAP therapy should be directed primarily against Pseudomonas
aeruginosa, which also provides aerobic Gram-negative coverage,
the usual pathogens in VAP. The potent anti-P. aeruginosa
antibiotics available today have sufficient activity that double drug
coverage is unnecessary. Double drug therapy does not decrease
resistance if a ‘high resistance potential’ antibiotic is used in the
combination. The study by Damas and colleagues in this issue of
Critical Care supports monotherapy for VAP. Optimal therapy for
VAP involves selecting a potent anti-P. aeruginosa antibiotic with a
‘low resistance potential’ that minimizes drug-drug interactions,
minimizes resistance, and is cost effective. Monotherapy of VAP
should be the standard of care.
Empiric antimicrobial therapy of ventilator-associated
pneumonia (VAP) should possess a high degree of activity
against aerobic Gram-negative bacilli (GNB). Although
Pseudomonas aeruginosa is not the most common VAP
pathogen, it is clearly the most virulent Gram-negative
pathogen. Antibiotics with a high degree of P. aeruginosa
activity are also effective against other aerobic GNB causing
VAP, that is, Escherichia coli,  Klebsiella pneumoniae and
Serratia marcescens. It is as important to know what
pathogens should be covered as it is to know which are not.
In VAP, respiratory secretions are commonly colonized by
nosocomial GNB that rarely cause VAP, for example,
Enterobacter species, Burkholderia (Pseudomonas) cepacia,
and  Sternotropmonas (Xanthomonas) maltophilia. In ‘early’
VAP, Streptococcus pneumoniae is a potential pathogen, but
in ‘late’ VAP, Gram-positive pathogens are uncommon.
Anaerobes are not important VAP pathogens [1].
The difficulties in determining the etiological agent in VAP are
well known. Many patients with fever, leukocytosis, and
pulmonary infiltrates on chest X-ray do not have VAP. Culture
of organisms from respiratory secretions in ventilated patients
does not imply a causal relationship to fever, leukocytosis,
and pulmonary infiltrates, and is not synonymous or
diagnostic of VAP [1-3]. In the critical care unit, ventilated
patients are commonly given antibiotics with good Gram-
negative activity but limited Gram-positive activity. For this
reason, colonization of respiratory secretions with Staphylo-
coccus aureus, either methicillin-susceptible (MSSA) or
methicillin-resistant (MRSA), is frequent, and the basis of
National Nosocomial Infections Surveillance (NNIS) VAP
data. Although respiratory secretion colonization with MSSA/
MRSA is exceedingly common, proven S. aureus VAP is
uncommon [1-3]. MSSA/MRSA pneumonia is a recognizable
clinical syndrome characterized by high fever, cyanosis, and
rapid cavitation on chest X-ray ≤72 hours.  S. aureus
necrotizing pneumonia is similar pathologically to P.
aeruginosa necrotizing pneumonia. Recovery of MSSA/
MRSA from respiratory secretions in ventilated patients with
fever/leukocytosis, and infiltrates is not diagnostic of S.
aureus VAP [1-4].
Besides potent anti-P. aeruginosa activity, the antibiotic
selected should have a ‘low resistance potential’, that is,
resistance not volume/duration related. ‘Low resistance
potential’ antipseudomonal antibiotics, such as cefepime and
meropenem, should be used preferentially over ‘high
resistance potential’ antibiotics, such as ceftazidime and
imipenem [5-7].
Monotherapy remains the rule for nearly all infections.
Combination therapy has been used to increase spectrum,
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provide synergy, or prevent resistance. Given the wide
spectrum of available antibiotics, it is rarely necessary to use
double drug therapy for increased spectrum [1,4].
Double drug coverage was used when potent GNB
antibiotics were limited and combinations were used for
potential synergy. Antibiotic combinations may be indifferent
or antagonistic and synergy is uncommon. Synergy should be
demonstrated by testing. Possible synergy is not a reason for
combination therapy, which may result in increased side
effects/interactions. Currently, antibiotics for VAP have potent
P. aeruginosa activity, and synergy is unnecessary [5,8].
Presently, prevention of resistance is the most frequently
given justification for double drug coverage. Prevention of
resistance by combining agents dates from decades past
when carbenicillin was combined with gentamicin to prevent
the emergence of P. aeruginosa carbenicillin resistance. This
exception has been extrapolated/extended into a general
concept, which it is not. Combination therapy per se does not
prevent resistance, and is the exception rather than the rule. If
ceftazidime, a ‘high resistance potential’ P. aeruginosa
antibiotic, is combined with a ‘low resistance potential’
antibiotic, for example, amikacin, the high resistance potential
of ceftazidime is not diminished/eliminated. The same is true
for nearly all other antibiotic combinations using high/low
resistance potential antibiotics. If ‘low resistance potential’
antibiotic monotherapy is selected for VAP, combination
therapy provides no additional benefit and needlessly
increases antibiotic costs [5-7]. Double drug therapy has no
benefit over monotherapy for VAP. Extensive experience
supports carefully selected empiric monotherapy for VAP as
optimal [9-14].
De-escalation therapy is a variant of combination therapy,
based on the notion that narrowing spectrum after initial
empiric broad spectrum therapy, after culture information is
reported, decreases resistance. Experience does not support
this concept. Broad spectrum β-lactam therapy, for example,
ceftriaxone, has been used extensively for decades for
pneumococcal pneumonia without resultant ceftriaxone-
induced  S. pneumoniae resistance. Changing to narrower
therapy, for example, penicillin after S. pneumoniae is
identified, makes little sense and clearly has no effect on
resistance [4]. Given the clinical difficulties of definitively
determining the putative pathogen in VAP without lung tissue,
narrow spectrum/specific therapy is often based on colonized
respiratory secretion cultures, which are often misleading [3].
Potent anti-P. aeruginosa ‘low resistance potential’ mono-
therapy eliminates the rationale for de-escalation therapy. As
the study by Damas and colleagues [15] demonstrates,
double drug therapy for VAP offers no advantages over
monotherapy. The authors have provided more data
supporting monotherapy as optimal therapy for VAP.
Pharmaco-economic imperatives argue strongly against
combination therapy for VAP. In an era of limited healthcare
resources, double drug therapy initially or for the duration of
VAP therapy is unnecessary and wasteful. Several antibiotics
are available for optimal empiric monotherapy of VAP,
including meropenem, cefepime, piperacillin/tazobactam,
levofloxacin, and so on. If clinicians choose wisely, selecting a
potent anti-P.  aeruginosa agent with a ‘low resistance
potential’, empiric monotherapy for VAP is highly effective
with minimal potential for resistance/drug interactions, and is
cost effective.
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